CD19/CD22双靶向CAR-T治疗儿童及青年复发难治B-ALL的1期试验
在15例儿童及青年复发/难治B-ALL患者中开展1期试验,评估同时表达抗CD19与抗CD22 CAR的AUTO3安全性。未报告剂量限制毒性或AUTO3相关重度细胞因子释放综合征/神经毒性,1个月缓解率86%(13/15),1年总生存率和无事件生存率分别为60%和32%。
要点
- AUTO3双靶向CAR-T未报告剂量限制毒性及AUTO3相关重度CRS或神经毒性。
- 治疗后1个月缓解率达86%(13/15),1年OS为60%、EFS为32%。
- 复发可能与AUTO3长期持久性有限有关,需改进CAR-T持久性策略。
核心结论
- AUTO3双靶向CD19和CD22的CAR-T在儿童及青年复发/难治B-ALL中达到研究终点,安全性可控且1个月缓解率较高。
研究设计与样本
- 1期试验(AMELIA,EUDRA CT 2016-004680-39)纳入15例儿童及青年复发/难治B-ALL患者,测试自体转导表达抗CD19和抗CD22 CAR的T细胞AUTO3。
- 主要终点为剂量限制毒性期内3-5级毒性发生率及剂量限制性毒性频率,次要终点包括微小残留病阴性形态学缓解率、不良事件、AUTO3扩增与持久性、B细胞发育不全持续时间及总生存和无事件生存。
主要发现
- AUTO3显示良好安全性特征,未报告剂量限制毒性或AUTO3相关重度细胞因子释放综合征或神经毒性病例。
- 治疗1个月后缓解率(完全缓解或完全缓解伴骨髓恢复不完全)为86%(13/15例)。
- 1年总生存率和无事件生存率分别为60%和32%。
- 复发可能归因于AUTO3长期持久性有限。
关键数值与推荐
- 1个月缓解率86%(13/15例),1年总生存率60%,1年无事件生存率32%。
临床怎么用
- 双靶向CD19/CD22 CAR-T在儿童及青年复发/难治B-ALL中安全性可控且短期缓解率高,但需关注长期持久性并探索提高持久性的策略。
局限性
- AUTO3长期持久性有限,可能与复发相关,需改进CAR-T持久性以充分发挥双靶向治疗潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T cells targeting CD19 or CD22 have shown remarkable activity in B cell acute lymphoblastic leukemia (B-ALL). The major cause of treatment failure is antigen downregulation or loss. Dual antigen targeting could potentially prevent this, but the clinical safety and efficacy of CAR T cells targeting both CD19 and CD22 remain unclear. We conducted a phase 1 trial in pediatric and young adult patients with relapsed or refractory B-ALL (n = 15) to test AUTO3, autologous transduced T cells expressing both anti-CD19 and anti-CD22 CARs (AMELIA trial, EUDRA CT 2016-004680-39). The primary endpoints were the incidence of grade 3-5 toxicity in the dose-limiting toxicity period and the frequency of dose-limiting toxicities. Secondary endpoints included the rate of morphological remission (complete response or complete response with incomplete bone marrow recovery) with minimal residual disease-negative response, as well as the frequency and severity of adverse events, expansion and persistence of AUTO3, duration of B cell aplasia, and overall and event-free survival. The study endpoints were met. AUTO3 showed a favorable safety profile, with no dose-limiting toxicities or cases of AUTO3-related severe cytokine release syndrome or neurotoxicity reported. At 1 month after treatment the remission rate (that is, complete response or complete response with incomplete bone marrow recovery) was 86% (13 of 15 patients). The 1 year overall and event-free survival rates were 60% and 32%, respectively. Relapses were probably due to limited long-term AUTO3 persistence. Strategies to improve CAR T cell persistence are needed to fully realize the potential of dual targeting CAR T cell therapy in B-ALL.
引用
- Cordoba S, Onuoha S, Thomas S, et al. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. Nat Med. 2021. PMID: 34642489. doi:10.1038/s41591-021-01497-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。